Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparison of Outcomes Between Low Dose Emicizumab and Extended Half-life Factor VIII With Pharmacokinetic-guided Prophylaxis in Clinically Severe Hemophilia A

NCT06155955 is registered in ClinicalTrials.gov with Chulalongkorn University as lead sponsor.

NCT NCT06155955
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06155955 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparison of Outcomes Between Low Dose Emicizumab and Extended Half-life Factor VIII With Pharmacokinetic-guided Prophylaxis in Clinically Severe Hemophilia A
Lead sponsor
Chulalongkorn University
Phase
Phase 2/3
Overall status
Unknown status
Start date
June 22, 2023
Completion date
June 21, 2024
Enrollment
15 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

joint bleed, severe hemophilia a without inhibitor